Mesenchymal Stem Cells as Immunomodulators After Liver Transplantation
Mesenchymal Stem Cells as Immunomodulators After Liver Transplantation
复制标题
DOI：
10.1002/lt.21862
复制
发表时间：
2009-10-01
影响因子：
4.6
通讯作者：
Dahlke, Marc H.
中科院分区：
文献类型：
--
作者：
Popp, Felix C.;Renner, Philipp;Dahlke, Marc H.
间充质干细胞（MSC）是免疫调节治疗的有前途的候选细胞，目前正在临床前和临床环境中进行测试。间充质干细胞在多种体外和疾病模型中抑制免疫反应，因此可能对患有自身免疫性疾病或移植排斥的患者有益。间充质干细胞调节免疫反应的机制仍在深入研究中，但它很可能涉及局部因子的表达，如吲哚胺 2,3-双加氧酶、诱导型一氧化氮合酶等，以及与树突状或抗原呈递细胞的相互作用。尽管间充质干细胞已在移植物抗宿主病以及心脏、肾脏和骨疾病的临床 I 期和 II 期研究中进行了评估，但仍热切期待将其引入实体器官移植。在这篇简短的综述中，我们总结了目前对 MSC 疗法实现的免疫调节的理解，并介绍了一项临床研究的可能纲要，该研究将在肝移植后无钙调神经磷酸酶抑制剂诱导方案的背景下使用 MSC。肝脏移植 15:1192-1198, 2009。(C) 2009 AASLD。
Mesenchymal stem cells (MSCs) are promising candidate cells for immunomodulation therapy that are currently being tested in the preclinical and clinical setting. MSCs suppress the immune response in a variety of in vitro and disease models and may thus be of benefit for patients suffering from autoimmune disorders or transplant rejection. The mechanism by which MSCs modulate the immune response is still under thorough investigation, but it most likely involves expression of local factors such as indoleamine 2,3-dioxygenase, inducible nitric oxide synthase, and others as well as interactions with dendritic or antigen-presenting cells. Although MSCs have been evaluated in clinical phase I and II studies for graft-versus-host disease and heart, kidney, and bone disease, their introduction into solid organ transplantation is still eagerly awaited. In this short review, we summarize the current understanding of immunomodulation achieved by MSC therapies and introduce a possible outline for a clinical study that will use MSCs in the context of a calcineurin inhibitor-free induction protocol after liver transplantation. Liver Transpl 15:1192-1198, 2009. (C) 2009 AASLD.